Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy

BACKGROUND: Tumor infiltrating lymphocytes (TILs) are associated with benefit to trastuzumab and chemotherapy in early-stage HER2+ breast cancer (BC) patients. The predictive value of TILs, TIL subsets, and other immune cells in patients receiving chemotherapy-sparing lapatinib plus trastuzumab (LT)...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: De Angelis, Carmine, Nagi, Chandandeep, Hoyt, Cliff C., Liu, Linying, Roman, Kristin, Wang, Chichung, Zheng, Yi, Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, Nuciforo, Paolo, Wang, Tao, Tsimelzon, Anna, Mao, Sufeng, Hilsenbeck, Susan G., Trivedi, Meghana V., Cataldo, Maria Letizia, Pavlick, Anne C., Wolff, Antonio C., Weigelt, Britta, Reis-Filho, Jorge S., Prat, Aleix, Gutierrez, Carolina, Osborne, C. Kent, Rimawi, Mothaffar F., Schiff, Rachel
Format: Artigo
Langue:Inglês
Publié: 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7002194/
https://ncbi.nlm.nih.gov/pubmed/31653641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1402
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires